Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2022—ZeptoMetrix announced the release of its NATtrol SARS-CoV-2 Omicron External Run Control, for research use only, to evaluate the performance of nucleic acid tests for determining the presence of SARS-CoV-2 omicron variant RNA. The control is formulated with purified, intact organisms and is for use with a real-time PCR thermal cycler. The product is available in six 0.5-mL vials and is refrigerator stable at 2° to 8°C.
June 2022—Siemens Healthineers announced the FDA has granted breakthrough device designation for the Advia Centaur serum neurofilament light chain (sNfL) assay, developed in collaboration with Novartis Pharma. The assay quantitatively measures NfL in human serum and plasma and is intended to be used in conjunction with clinical, imaging, and laboratory findings as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower risk, versus higher risk, of multiple sclerosis disease activity.
June 2022—Bio-Rad Laboratories introduced a range of antibodies specific to cemiplimab (Libtayo) that inhibit the binding of the drug to its target, human programmed death receptor-1. The ready-made antibodies are suitable for developing selective and sensitive assays for the bioanalysis and drug monitoring of cemiplimab.
June 2022—Nova Biomedical launched the CE-marked Nova Max Pro creatinine/eGFR meter system in the EU market. Nova Max Pro is designed to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The meter and creatinine biosensor measure blood creatinine and calculate estimated glomerular filtration rate from a 1.2-μL capillary fingerstick blood sample in 30 seconds. The measuring technology is based on the Nova StatSensor Creatinine technology.
June 2022—Seegene announced that its Allplex RV Master Assay has achieved CE-IVD marking and received approval from Australia’s Therapeutic Goods Administration.
June 2022—PreciseDx announced its AI-enabled digital pathology technology can accurately diagnose Parkinson’s disease in patients prior to severe onset of symptoms.
June 2022—Versant Diagnostics has announced a strategy in which the company will focus on anatomic pathology, precision medicine, and the digital transformation of the industry. The company said it is positioning itself to become the nation’s largest independent physician services company through the acquisition of independent pathology practices, and it will provide capital for practices to convert to digital pathology while maintaining physician leadership.
April 2022—Paragon Genomics announced the release of its Emerging Variant Add-on V2. The panel is designed to be used with existing CleanPlex SARS-CoV-2 products, the company says, to maintain high coverage for variant calling and identification as the virus evolves. It includes added primers for enhanced coverage of critical variants, such as alpha, beta, delta, mu, and omicron, and has been confirmed in silico to cover the defining and characteristic mutations of the omicron sublineages, BA.1, BA.2, and BA.3.
April 2022—Thermo Fisher Scientific has launched two reverse transcription loop-mediated isothermal amplification (RT-LAMP)–based solutions for research use only. The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2, is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal, or nasopharyngeal swab samples. The kit includes two protocols, one for crude sample types with a 30-minute turnaround time and one for increased sensitivity with purified RNA sample types that has a one-hour turnaround time.
April 2022—Verichem Laboratories offers two multilevel, protein-based test kits of clinical reference materials for the calibration or calibration verification of lithium assays. Intended for use with direct and indirect ion-selective electrodes, colorimetric assays, and flame photometers, the Electrolyte Standard Kit and Serum ISE Standard Kit contain NIST-verified gravimetric concentrations for lithium. The liquid-stable, ready-to-use materials can also be used for quality control monitoring, method evaluations, post-maintenance testing, and routine troubleshooting.
